Skip to main content

Table 3 Multivariate analysis with regard to tumor progression or death

From: Effect of long-term adjuvant temozolomide chemotherapy on primary glioblastoma patient survival

 

Patient number

PFS

P

OS

P

HR

HR

(95%CI)

(95%CI)

MGMT methylation

 No

23

1

 

1

 

 Yes

26

0.336

0.002

0.470

0.025

  

(0.167–0.674)

 

(0.243–0.909)

 

IDH

 Wild type

29

1

 

1

 

 Mutation

10

0.094

 

0.077

 
  

(0.026–0.346)

< 0.001

(0.016–0.384)

0.002

TMZ therapeutic cycles

 6

27

1

 

 

  > 6

26

0.224

< 0.001

 
  

(0.106–0.473)

 

Brain lobes involved in tumor

 Single lobe

34

1

   

 Multiple lobes

19

0.406

0.012

 
  

(0.201–0.819)

 

Pre-surgery KPS score

  < 80

11

 

1

 

  > 80

42

 

0.192

< 0.001

  

(0.079–0.464)

 
  1. Abbreviations: CI Confidence interval, KPS Kanovsky performance score, MGMT O-6-methylguanine-DNA-methyltransferase, IDH Isocitrate dehydrogenase, HR Hazard ratio